// App-Quantinova.ai

P176 : Minimal important difference, minimal detectable change and disease activity thresholds for two novel composite instruments, three visual analogue scale/VAS and four visual analogue scale/VAS, in patients with psoriatic arthritis: pooled analysis of three phase III studies

Researchers

Presenter

  • William Tillett

Principal Investigators

  • Laura Coates

  • Marijn Vis

  • Joseph Merola

  • Enrique Soriano

  • Michelle Perate

  • May Shawi

  • Miriam Zimmermann

  • Emmanouil Rampakakis

  • Mohamed Sharaf

  • Peter Nash

  • Philip S Helliwell

Medical Centers

  • School of Medicine, Griffith University and University of Queensland, Maroochydore, Australia

  • Departments of Dermatology and Medicine, Division of Rheumatology, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA

  • Rheumatology Unit and University Institute, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina

  • Nuffield Department of Orthopaedics Rheumatology and Musculoskeletal Sciences, University of Oxford, University of Oxford, Oxford, United Kingdom

  • Johnson and Johnson Middle East, Johnson and Johnson, Dubai, UNITED ARAB EMIRATES

  • Erasmus University Medical Center, Rotterdam, Netherlands

  • Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK

  • Department of Oncology, McGill University, Montreal, QC, Canada

  • Royal National Hospital for Rheumatic Diseases and University of Bath, Bath, United Kingdom

Locations

  • Australia

  • Netherlands

  • United States

  • United Kingdom

  • Argentina

  • Canada

  • Switzerland

Companies

  • N/A

Study Components

Therapeutic Area

  • Dermatology

  • Musculoskeletal

Disease

  • Psoriatic arthritis

Biomarkers

  • C-C Motif Chemokine Ligand 22

Drug/Treatment

  • Grace

Outcome

  • N/A

Study Design

  • N/A

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved